Summary
Details
- European Union
Mandatory: marketing authorization, safety, quality and efficacy compliance.
Functionally mandatory: ERA for relevant medicinal product applications.
Stronger requirements: antibiotics, environmentally persistent substances, high-volume medicines and products with significant water impacts.
Deep dive
- uired
- 1. Environmental Risk Assessment for Medicines
- 2. Pharmaceutical Reform and Stronger Environmental Governance
- 3. Manufacturing, APIs and Supplier Governance
- 4. Pharmaceuticals in the Environment and Water Governance
- 5. Antimicrobial Resistance and One Health Requirements
- 6. Scope 3, Procurement and Healthcare Value Chain Implications
- 7. Audit, Verification and Monitoring Systems
- 8. Procurement Integration and Supplier Segmentation
- Important Deadlines
- Current Status
- Penalties for Non-Compliance
- Examples of Known Failure Modes
- Resources
📩 Stay ahead of climate regulation and reporting shifts
Regulatory updates, reporting standards, and new climate software — distilled into one concise weekly brief for decision-makers.
Thanks for signing up. Please check your inbox to confirm your subscription.
Practical updates. Once per week.
uired
EU pharmaceutical legislation is not one single chemical regulation.
It is a regulatory framework for medicinal products, built around the EU medicines authorisation system and now being reformed to address:
Access.
Supply security.
Innovation.
Antimicrobial resistance.
Environmental sustainability.
The current reform package aims to modernise EU pharmaceutical law and includes a proposed Directive on the Union code relating to medicinal products for human use, replacing:
Directive 2001/83/EC.
Directive 2009/35/EC.
The architecture integrates:
Marketing authorisation requirements.
Quality, safety and efficacy standards.
Environmental risk assessment.
Good manufacturing practice.
Pharmacovigilance.
Antimicrobial resistance measures.
Medicine availability and shortage rules.
Supply chain obligations.
Environmental sustainability objectives.
Urban wastewater micropollutant cost responsibility.
This creates a medicine lifecycle governance model, where pharmaceutical products are regulated from development and authorisation through manufacture, use, disposal and environmental impact.
1. Environmental Risk Assessment for Medicines
Environmental Risk Assessment, known as ERA, is a central chemical-environmental element of EU pharmaceutical governance.
Marketing authorisation applicants must assess potential environmental risks from medicinal products.
ERA may consider:
Persistence.
Bioaccumulation.
Toxicity.
Aquatic impacts.
Soil impacts.
Exposure from patient use.
Manufacturing and disposal pathways.
Risk mitigation measures.
Antimicrobial resistance relevance.
The European Medicines Agency states that the purpose of its ERA guideline is to describe the assessment of potential environmental risks of human medicinal products, including risk mitigation measures to limit environmental impact.
This creates a pre-market environmental assessment model, where medicine approval is linked to environmental data and risk mitigation.
2. Pharmaceutical Reform and Stronger Environmental Governance
The EU pharmaceutical reform aims to make medicines more environmentally sustainable and to address antimicrobial resistance and pharmaceuticals in the environment through a One Health approach.
The reform is expected to strengthen:
ERA requirements.
Environmental risk mitigation.
AMR-linked obligations.
Lifecycle environmental consideration.
Supply chain transparency.
Availability and shortage management.
Regulatory incentives and obligations.
This creates a next-generation pharmaceutical environmental governance layer, where medicines are increasingly treated not only as healthcare products but also as chemical substances with environmental pathways.
3. Manufacturing, APIs and Supplier Governance
Pharmaceutical supply chains are complex and chemically intensive.
Affected actors include:
Marketing authorisation holders.
API manufacturers.
Excipient suppliers.
Contract development and manufacturing organisations.
Packaging suppliers.
Laboratories.
Logistics providers.
Wholesalers.
Healthcare procurement bodies.
Companies must manage:
GMP compliance.
Quality systems.
Chemical process controls.
Solvent and waste management.
Water use.
API residues.
Batch traceability.
Supplier qualification.
Shortage risk.
Environmental and safety documentation.
This creates a pharmaceutical chemical supply chain governance model, where supplier performance affects:
Quality.
Regulatory compliance.
Environmental risk.
Medicine availability.
4. Pharmaceuticals in the Environment and Water Governance
Medicines can enter the environment through:
Patient excretion.
Improper disposal.
Manufacturing discharges.
Hospital wastewater.
Agricultural use of veterinary medicines.
Waste treatment pathways.
The revised Urban Waste Water Treatment Directive introduces a major new link between pharmaceutical products and environmental cost responsibility.
The European Commission states that pharmaceutical and cosmetics industries will be required to pay at least 80% of the cost of removing micropollutants under the new wastewater rules.
This creates a polluter-pays micropollutant governance layer, where pharmaceutical companies are no longer affected only through product authorisation but also through downstream wastewater treatment costs.
5. Antimicrobial Resistance and One Health Requirements
EU pharmaceutical reform is closely linked to antimicrobial resistance.
AMR governance affects:
Antibiotic development.
Responsible use.
Environmental release of antimicrobials.
Manufacturing discharges.
Healthcare stewardship.
Veterinary and human medicine interfaces.
Wastewater monitoring.
The Commission’s reform objectives explicitly include addressing antimicrobial resistance and the presence of pharmaceuticals in the environment through a One Health approach.
This creates a health-environment risk governance model, where medicine regulation, water pollution and public health are increasingly connected.
6. Scope 3, Procurement and Healthcare Value Chain Implications
Pharmaceutical legislation affects Scope 3 and procurement because healthcare systems increasingly require medicine suppliers to disclose and reduce environmental impacts.
It affects:
Purchased medicines.
Hospital procurement.
API supply chains.
Packaging.
Cold chain logistics.
Waste disposal.
Medicine take-back schemes.
Water pollution exposure.
Supplier due diligence.
Healthcare decarbonisation strategies.
Companies may need to provide:
Product environmental data.
Supplier quality and sustainability data.
Manufacturing location information.
Shortage risk information.
Environmental risk mitigation plans.
Packaging and disposal information.
This creates a healthcare product-level Scope 3 governance model, where medicine procurement is increasingly linked to:
Chemical data.
Environmental data.
Supply chain data.
7. Audit, Verification and Monitoring Systems
Compliance is enforced through:
EMA scientific assessment.
National competent authorities.
Marketing authorisation procedures.
GMP inspections.
Pharmacovigilance systems.
Environmental risk assessment review.
Wastewater producer responsibility schemes.
Healthcare procurement audits.
Supply chain shortage monitoring.
Companies must:
Maintain authorisation dossiers.
Update environmental data where required.
Comply with GMP.
Monitor adverse effects.
Manage quality systems.
Maintain supplier controls.
Support inspections.
Comply with wastewater-related producer responsibility where applicable.
This creates a multi-layer pharmaceutical verification regime, combining:
Medicines regulation.
Environmental assessment.
Manufacturing inspections.
Emerging micropollutant governance.
8. Procurement Integration and Supplier Segmentation
Suppliers are segmented based on:
API criticality.
Medicine type.
Environmental risk.
AMR relevance.
Manufacturing location.
Water and waste exposure.
Shortage risk.
Healthcare procurement importance.
Cold chain requirements.
High-risk suppliers face:
Stronger qualification requirements.
GMP scrutiny.
Environmental data requests.
Water and waste controls.
Supply continuity requirements.
Corrective action plans.
Potential exclusion from procurement.
This creates a risk-based pharmaceutical supplier governance model, especially for:
APIs.
Antibiotics.
High-volume medicines.
Environmentally persistent substances.
Important Deadlines
Key timelines include:
Ongoing marketing authorisation and ERA requirements.
2023 Commission proposal for EU pharmaceutical reform.
2024 European Parliament position on the reform process.
2024 adoption of revised Urban Waste Water Treatment Directive.
2045 deadline for advanced treatment to reduce micropollutants in larger plants under the wastewater framework.
Ongoing EMA guideline updates and Q&A updates.
Future implementation dates dependent on final adoption of pharmaceutical reform.
The Commission’s pharmaceutical reform page confirms the revision aims to make medicines more environmentally sustainable and address AMR and pharmaceuticals in the environment.
The Urban Waste Water Treatment Directive adds a separate but related implementation pathway for micropollutant removal costs, with pharmaceutical and cosmetics producers covering at least 80% of advanced treatment costs.
Current Status
The framework is active and under reform.
Current pressure points include:
Stronger ERA requirements.
Pharmaceuticals in water.
AMR and One Health.
API supply chain resilience.
Medicine shortages.
Environmental manufacturing standards.
Wastewater micropollutant costs.
Healthcare procurement sustainability.
Packaging and disposal impacts.
The EMA states that information is available on upcoming changes introduced by the EU’s comprehensive overhaul of pharmaceutical legislation, reflecting the ongoing reform process.
Penalties for Non-Compliance
Enforcement may include:
Refusal of marketing authorisation.
Request for additional ERA data.
Suspension or variation of authorisation.
GMP enforcement action.
Product withdrawal.
Healthcare procurement exclusion.
Financial contributions under wastewater EPR schemes.
Corrective action requirements.
Regulatory penalties under national law.
This links pharmaceutical environmental performance to:
Product approval.
Manufacturing compliance.
Market access.
Examples of Known Failure Modes
Typical risks include:
Incomplete environmental risk assessment.
Poor API manufacturing controls.
Uncontrolled manufacturing discharges.
Insufficient AMR risk mitigation.
Lack of environmental data for procurement.
Improper medicine disposal.
High micropollutant contribution to wastewater.
Weak supplier quality oversight.
Shortage risks from fragile supply chains.
Packaging and cold chain inefficiencies.
Resources
Cut through the green tape
We don't push agendas. At Net Zero Compare, we cut through the hype and fear to deliver the straightforward facts you need for making informed decisions on green products and services. Whether motivated by compliance, customer demands, or a real passion for the environment, you’re welcome here. We provide reliable information. Why you seek it is not our concern.